PMVPライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:50):

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer...

Stats
本日の出来高	56 509.00
平均出来高	571 948
時価総額	90.03M
EPS	$0 ( 2024-03-06 )
次の収益日	( $-0.350 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.220
ATR14	$0.00400 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-18	Jalota Deepika	Buy	225 095	Employee Stock Option (right to buy)
2024-01-18	Jalota Deepika	Buy	95 555	Common Stock
2024-01-18	Carulli Michael	Buy	204 630	Employee Stock Option (right to buy)
2024-01-18	Carulli Michael	Buy	82 220	Common Stock
2024-01-18	Mack David Henry	Buy	519 915	Employee Stock Option (right to buy)

INSIDER POWER
60.27
Last 97 transactions
Buy: 3 540 873 \| Sell: 1 925 887

ボリューム相関

長: 0.18 (neutral)

短: 0.62 (weak)

Signal:(40.729) Neutral

PMV Pharmaceuticals, Inc. 相関

10 最も正の相関
FCBC	0.942
HOL	0.938
EVLO	0.937
LGMK	0.935
FIBK	0.935
EQBK	0.935
GRNA	0.933
BHTG	0.931
SLNG	0.928
LYEL	0.928

10 最も負の相関
GVCI	-0.96
APTM	-0.958
SCRM	-0.956
DPCS	-0.956
CCTS	-0.955
ORIA	-0.954
TIOA	-0.954
XPAX	-0.953
ARRW	-0.951
FRONU	-0.951

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

PMV Pharmaceuticals, Inc. 相関 - 通貨/商品

-0.66
( moderate negative )

0.00
( neutral )

-0.57
( weak negative )

0.75
( moderate )

0.66
( moderate )

PMV Pharmaceuticals, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.26M (0.00 %)
EPS:	$-1.440

FY	2023
収益:	$0
総利益:	$-1.26M (0.00 %)
EPS:	$-1.440

FY	2022
収益:	$0
総利益:	$-650 000 (0.00 %)
EPS:	$-1.610

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.277

Financial Reports:

No articles found.

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.